Molecular mechanisms of oncostatin M (OSM)-stimulated cartilage extracellular matrix catabolism and signaling pathways were investigated in human arthritic chondrocytes. OSM, alone or with Interleukin-1 (IL-1β), increased glycosaminoglycan release and induced ADAMTS-4 and MMP-13 protein expression in human cartilage explants. OSM dose-and time-dependently increased ADAMTS-4 mRNA and MMP-13 protein expression in human femoral head chondrocytes. Extracellular signal-regulated kinases (ERK1/2)-MAPK pathway inhibitor, U0126, downregulated ADAMTS-4 and MMP-13 induction by OSM. Janus kinase 2 (JAK2) inhibitor, AG490, suppressed OSM-induced ADAMTS-4 mRNA expression but did not affect MMP-13 levels while JAK3 pharmacological inhibitor and siRNA transfection suppressed both. Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. Additionally, OSM-enhanced ADAMTS-4 mRNA and MMP-13 expression was down-regulated by phosphatidylinositol 3-kinase (PI3K) and Akt/PKB inhibitors, LY294002 and NL-71-101. Furthermore, JAK3 inhibition timedependently down-regulated Akt but not ERK1/2 phosphorylation suggesting that Akt is a downstream target of JAK3. These results suggest that OSM-stimulated ADAMTS-4 and MMP-13 expression is mediated by ERK1/2, JAK3/STAT1/3 and PI3K/Akt and by cross talk between these pathways. The inhibitors of these cascades could block OSM-evoked degeneration of cartilage by ADAMTS-4 and MMP-13.
Introduction
The integrity of cartilage depends upon balance between matrix-degrading matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that is controlled by the levels of proinflammatory and antiinflammatory cytokines. These homeostatic balances are altered in arthritic joints due to excessive proinflammatory cytokines derived from endogenous and exogenous cells in synovium and cartilage [1, 2] . Oncostatin M (OSM), a major cytokine produced by macrophages, neutrophils [3] and T cells, has both pro-and anti-inflammatory activities in vivo. Its levels are elevated in the patients with rheumatoid arthritis (RA) [4] . OSM by itself contributes to cartilage and bone loss in RA [5] . Blocking antibodies to OSM in mouse models of RA ameliorate arthritis [6] . Although not elevated in osteoarthritic (OA) synovial fluid [4] , specific interaction of OSM with interstitial collagens [7] may contribute to its availability and local activities.
Loss of principal cartilage proteoglycan, aggrecan (which gives compressive stiffness) in arthritis occurs by multiple proteases. By measuring the activity with an aggrecan neoepitope antibody, aggrecanases or ADAMTS (A Disintegrin And Metalloproteinase with thrombospondin motifs) were shown to cleave efficiently at multiple sites of the aggrecan core protein including between Glu 373 -Ala 374 [8] . ADAMTS-4 also cleaves at MMP site, Asn 341 -Phe 342 [9] . The c-terminal thrombospondin motif (TSP-1) of aggrecanase-1 binds with glycosaminoglycans of aggrecan and is critical for substrate recognition and cleavage [10] . ADAMTS-4generated products are found in the cartilage and synovial fluid Biochimica et Biophysica Acta 1773 (2007) 309 -320 www.elsevier.com/locate/bbamcr of OA patients indicating its prominent role in aggrecan catabolism [11] . OSM and IL-1 combination induces ADAMTS-4 RNA in human chondrocytes [12] . Both ADAMTS-4 and-5 are expressed in human arthritic synovium, though only former is inducible [13] and ADAMTS-4 cleaves aggrecan 2 times faster than ADAMTS-5 [14] . However, ADAMTS-5 is important for cartilage degradation in the mouse models of OA and RA [15, 16] . The role of this enzyme in human arthritis remains to be elucidated. Thus, proteases from both synovial linings and chondrocytes can cause cartilage degradation. Aggrecanases are key targets for developing cartilage protective therapies, however, nothing is known about the proinflammatory/catabolic cytokine signaling and regulatory mechanisms controlling their expression in human femoral chondrocytes. MMP-13 (collagenase-3) is another major enzyme that cleaves and denatures type II collagen 5-10 times more effectively than collagenase-1 in OA cartilage [17, 18] . It also cleaves aggrecan at a different site [19] . Its expression is increased in OA cartilage [20] . Direct injection into knee or cartilage-specific overexpression of active human MMP-13 in joints led to tissue damage in transgenic mice, suggesting major implication of this enzyme in arthritis [21] . OSM alone and with other proinflammatory cytokines induces MMP-13 in articular chondrocytes [22] . Cytokine-stimulated proteolytic actions of aggrecanases followed by MMP-13 result in degradation of matrix components in human arthritic tissues and their inhibition is a valid therapeutic approach.
OSM stimulates ERK1/2, JNK1/2, p38 kinase and JAK/ STAT activation in chondrocytes [22] . The PI3 kinase and its downstream kinases such as Akt/PKB kinase play a fundamental role in many biological functions such as cell growth, differentiation, survival, cytoskeletal organization, cell motility and inflammation [23] . The current study was aimed to identify the signal transduction pathways implicated in ADAMTS-4 induction by OSM compared to those of MMP-13. We demonstrate that OSM-induced ADAMTS-4 and MMP-13 expression is mediated by ERK, JAK/STAT and PI3K/Akt pathways in primary human chondrocytes from arthritic patients.
Experimental procedures

Materials
Recombinant human OSM and IL-1β were from R&D Systems (Minneapolis, MN). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum were purchased from Invitrogen (Burlington, ON). Human chondrosarcoma cell line, SW1353 was obtained from American Type Culture Collection (Manassas, VA). The phospho-specific p44/42 ERK (T202/Y204) E10 monoclonal and Akt/PKB antibodies were purchased from Cell Signaling (Pickering, ON). ADAMTS-4 (ab-16297) antibody was from Abcam (Cambridge, MA). Double-stranded STAT3 consensus oligonucleotides were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). U126, LY-294002, NL-71-101, JAK3 inhibitor I, and AG490 were from Calbiochem (La Jolla, CA). Nitrocellulose membranes were from Bio-Rad (Mississauga, ON). Enhanced chemiluminescence (ECL) reagent, leupeptin, pepstatin, aprotinin and fungal (Streptomyces griseus) pronase were from Roche Diagnostics (Laval, QC). MMP-13 (M4052) antibody (that detects both pro-and active forms of enzyme), bacterial (Clostridium histolyticum) collagenase type 1A and all other reagents were from Sigma (St. Louis, MO). JAK3 SMART pool siRNAs were purchased from Upstate (Lake Placid, NY). TransAM™ AP-1 assay kit was from ActiveMotif (Carlsbad, CA).
Methods
Human cartilage explants, culture of primary chondrocytes and SW1353 chondrocytic cells
The use of human tissues was approved by the institutional ethics committee. Human articular cartilage was obtained from the femoral heads of patients undergoing hip replacement surgery due to late-stage OA (female n = 15 and age between 46 and 97 years, male n = 12 and age between 47 and 89 years). Cartilage fragments (40-45 mg) were excised from the superficial and medial layers and cultured in 2 ml of DMEM supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100 μg/ml) for 24 h prior to stimulating with different cytokines. For cell culture, immediately after harvesting the cartilage, the pieces were digested first with pronase for 60 min and then with collagenase for 9 h in DMEM. The chondrocytes were washed with phosphate buffered saline (PBS) and grown in DMEM supplemented with 10% FCS as high-density primary monolayer cultures until confluent growth. Cells were distributed in 6-well plates, grown to confluence, washed with PBS and kept in serum-free DMEM for 48 h. Human chondrosarcoma cell line, SW1353, was treated as described below for primary chondrocytes.
Glycosaminoglycan measurement by DMMB assay
Explants of human cartilage (40-45 mg) were stimulated with OSM (50 ng/ ml) and/or IL-1β for 3 days in DMEM. Conditioned media were used to evaluate MMP-13 expression by Western blot and glycosaminoglycan (GAG) content by the dimethylmethylene blue (DMMB) assay based on the procedure of Farndal et al. [24] .
RNA extraction and RT-PCR
Total RNA was extracted as previously described and aliquots of 3-5 μg analyzed by electrophoretic fractionation in 1.2% formaldehyde-agarose gels [22] . The integrity and quantity of applied RNA were verified by ethidium bromide staining of the gels and photography of the 28S and 18S ribosomal RNA bands. For RT-PCR, 2 mg of RNA was heated for 5 min at 65°C and reverse transcribed in the mixture consisting of oligo d (T) 12-18mer, dNTPs, RNase inhibitor (Pharmacia), acetylated BSA (Promega) with Moloney murine leukemia-virus reverse transcriptase (MMLV-RT) (Invitrogen) according to the protocols of Clontech Laboratories Inc. (Paolo Alto, CA). Conditions of RT-PCR were same as described before for aggrecanase-1-specific primers [25] . The amplification profile was one cycle at 94°C for 1 min, 35 cycles of 94°C for one min, hybridization at 60°C for 2 min and extension at 72°C for 3 min., followed by one extension cycle of 7 min at 72°C. The PCR was performed in a DNA cycler (Techne, Princeton, NJ) in a 50-ml reaction with 1.25 mM dNTPs, Taq DNA polymerase (Pharmacia) and respective primers. Aliquots of 10 ml from the 50 ml PCR reaction were analyzed on 1.4% agarose gels to detect ADAMTS-4 and glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA amplification products of 692 and 226 bp respectively. Negative controls included either all the RT-PCR reagents except cDNA or additionally, RT was omitted before PCR. None of these controls gave any bands. Semiquantitative estimates were obtained with NIH ImageJ 1.32j (National Institute of Health, USA) software by dividing ADAMTS-4 band intensities with those of GAPDH.
Western blot analysis
For measuring MMP-13 expression levels, chondrocytes were preincubated with different inhibitors (U0126 or parthenolide 5, 10 μM), JAK3 inhibitor (10, 30 μg/ml), LY-294002 and NL-71-101 (10, 20 μM) for 30 min. Cells were then stimulated with OSM (50 ng/ml) for 24 h. Total secreted proteins from 2 ml of conditioned medium of chondrocytes were concentrated by precipitation with trichloroacetic acid (TCA) and quantified by the Bio-Rad protein assay system. Proteins (5 μg) were separated by 10% SDS-PAGE. Blots were blocked in TBS-T containing 5% dry milk for 20 min at 37°C. Thereafter, blots were probed with a polyclonal antibody against MMP-13 (1/1000 dilution) in blocking buffer at 4°C overnight. Subsequently, membranes were washed in TBS-T buffer five times for 5 min. Detection was carried out using anti-rabbit horseradish peroxidase-conjugated IgG (1/5,000 dilution) in blocking buffer. Blots were developed by Enhanced Chemiluminescence (ECL). Band intensities were quantified by NIH ImageJ 1.32j (National Institute of Health, USA) software.
For Western blot analysis of ADAMTS-4, explants were stimulated with OSM and/or IL-1β for 3 days, frozen in liquid nitrogen immediately and stored at − 80°C. Frozen explants were pulverized under liquid nitrogen and proteins in the resulting powder were extracted with Tris buffer (50 mM Tris, pH 7.0, 100 mM NaCl and 1 μg/ml aprotinin, 0.7 μg/ml pepstatin, 1 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) for 20 h. Extracts were lyophilised for 4 h to concentrate the proteins. Total protein (50 μg) was separated by electrophoresis on a 10% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. Blots were treated as described above. Membranes were incubated with specific antibodies to ADAMTS-4 (abcam-ab162970) at dilutions of 1:500 (overnight at 4°C) and second antibody (1/5000, 1 h at room temperature).
For Western blot analysis of phosphorylated ERK1/2 and Akt/PKB, human chondrocytes were pretreated for each time point with JAK3 inhibitor (30 μg/ml) and then stimulated with OSM (0-30 min). These cells were washed three times with cold PBS and lysed in a buffer which contained 20 mM HEPES (pH 7.5), 20 mM NaCl, 1 mM orthovanadate, 1 mM sodium fluoride, 5 mM EDTA, 1% Nonidet P-40, 1 μg/ml aprotinin, 0.7 μg/ml pepstatin, 1 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were centrifuged at 14,000 rpm for 20 min. Proteins (15 μg) were separated by 10% SDS-PAGE. Blots were treated as described above. Polyclonal phospho-specific antibodies against ERK1/2 or Akt/PKB (1/1,000 dilution) in blocking buffer at 4°C overnight were used to detect the active forms of these kinases. The same p-ERK1/2 and p-Akt/PKB nitrocellulose membranes were used to probe the total forms of ERK1/2 and Akt/PKB without stripping.
Electrophoretic mobility shift assay (EMSA)
SW1353 cells in 6-well plates were grown to 100% confluence, washed with PBS and kept in serum-free DMEM for 48 h. Parthenolide was added at a concentration of 5-10 μM respectively 30 min before treatment with human OSM (50 ng/ml). Nuclear extracts were prepared as described [26] with some modifications. After 40 min treatments, the cells were washed twice with cold PBS (pH 7.4) and detached by scraping, recovered by centrifugation at 10,000 rpm for 5 min at 4°C. The cells were lysed in ice cold buffer A [10 mM HEPES (pH 7.9), 1.5 mM MgCl 2, 10 mM KCl, 0.5 mM DTT, 1 mM PMSF, 1% NP 40, 1 mM NaF and 10 mg/ml protease inhibitors leupeptin A and pepstatin] and mixed by pipetting. After incubation on ice for 10 min, the contents were centrifuged at 4000 rpm for 2 min. The nuclear pellets were suspended in 60 ml of ice cold buffer B [20 mM HEPES (pH 7.9), 420 mM NaCl, 25% glycerol, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM NaF, 0.5 mM DTT, 0.5 mM PMSF and 10 mg/ml protease inhibitors, leupeptin and pepstatin A] and kept on ice for 30 min with gentle shaking and then centrifuged at 12,000 rpm for 15 min at 4°C
. The nuclear protein supernatants were recovered and protein concentrations were determined by Bio-Rad protein assay. The double-stranded oligonucleotide containing the STAT3 consensus (Santa Cruz Biotechnology) sequence was end labeled with [γ-p 32 ] ATP by T4 polynucleotide kinase. Nuclear extracts (5 mg) were incubated with 20,000 CPM of labeled probe for 20 min at room temperature in binding buffer [10 mM Tris-HCl (pH 7.5), 4% glycerol, 1 mM MgCl 2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl and 50 mg/ml poly (dI. dC)] and DNA protein complexes were resolved on a 5% non-denaturing polyacrylamide gel at room temperature. The TransAM AP-1 family kit was used to measure c-Fos and c-Jun activation and nuclear binding. The methodology was based on the manufacturer's instructions.
Transfection of siRNA by Calcium phosphate method
Suspended SW1353 chondrosarcoma cells (5 × 10 5 cells) were incubated with 100 nM of JAK3 SMART pools siRNA by Calcium phosphate precipitation method for 20 min and seeded in 10% serum-containing media for 4 h. Culture medium was removed, cells were washed with PBS and fresh medium was added for 24 h at 37°C in 5% CO2-95% air. Thereafter, cells were incubated for 24 h in serum-free media and then stimulated with OSM for 24 h.
Statistical analysis
Results are reported as means± SE and were compared by ANOVA, followed by a post hoc Newman-Keuls multiple comparison test. P < 0.05 was considered significant.
Results
Oncostatin M and Interleukin 1 promote aggrecan degradation and ADAMTS-4 and MMP-13 expression in human cartilage explants
To evaluate the impact of OSM and IL-1β on human chondrocytes in their native extracellular matrix, cartilage explants were stimulated with OSM (50 ng/ml) and/or IL-1β. OSM alone or in combination with IL-1β increased glycosaminoglycan (GAG) release in the media after 3 days (∼ 3 fold) (Fig. 1A) . The two separate treatments increased the GAG release at the same magnitude and combined stimulation of OSM and IL-1β did not show any synergistic effect. Fig. 1B shows the active form of ADAMTS-4 expression induced by OSM in human cartilage after 3 days of stimulation. This is likely to be the major active ADAMTS-4 form since IL-1α enhances the production of this form in cartilage [27] . The results from two different patients show the levels of MMP-13 protein expression induced by OSM, IL-1β and combined OSM and IL-1β treatments (Fig. 1C) . OSM or IL-1β alone induced MMP-13 expression. The combination of these cytokines had an additive effect on MMP-13 proenzyme and active form expression. The basal levels of MMP-13 expression were found to be elevated in some patients (as in patient 1). Despite differences in the basal MMP-13 expression, the profiles of OSM and IL-1β responses were the same. 
Oncostatin M alone induces ADAMTS-4 and MMP-13 expression in human chondrocytes
The responsiveness of human chondrocytes to OSM was evaluated by stimulating the cells with increasing doses of OSM (1-100 ng/ml). OSM dose-dependently increased ADAMTS-4 mRNA expression and MMP-13 proenzyme or its active form expression in human chondrocytes ( Fig. 2A) . The minimal dose of 10 ng/ml of OSM was sufficient to induce the expression of both enzymes. However, an effective dose of 50 ng/ml was used in subsequent experiments. OSM caused a time-dependent increase of ADAMTS-4 and MMP-13 mRNA by 16 h that lasted until 32 h (Fig. 2B ). Further, OSM and IL-1β (10 ng/ml) had an additive effect on ADAMTS-4 mRNA and MMP-13 expression ( Fig. 2C ). GAPDH control mRNA expression was unaffected by these treatments. We measured ADAMTS-4 mRNA because the amount of protein of this enzyme was quite low or even undetectable after 24-h stimulation of chondrocytes with OSM grown in 6-wells plates.
ERK pathway inhibition suppresses OSM-induced ADAMTS-4 and MMP-13 expression
To investigate the role of ERK-MAPK pathway in OSM induction of ADAMTS-4 and MMP-13 expression, primary human femoral head OA chondrocytes were pre-treated with an inhibitor of this pathway, U0126, which inhibits the inactive and active MEK-1/2 [28] , and then stimulated with OSM. ADAMTS-4 mRNA ( Fig. 3A and B ) and the active form of MMP-13 protein ( Fig. 3C and D) expression were potently induced by OSM over the basal levels and U0126 dosedependently reduced their induction. GAPDH control mRNA expression was unaffected by these treatments. Since the basal level of the MMP-13 proenzyme varies among the 
JAK3 inhibitor and siRNA down-regulate OSM-stimulated ADAMTS-4 and MMP-13 expression
Since JAK/STAT pathway mediates OSM induction of MMP-13 [22] , we investigated the role of this cascade in OSMstimulated ADAMTS-4 gene expression. MMP-13 was also analyzed for comparison. Pretreatment with JAK3-specific inhibitor at different concentrations (10-30 μg/ml) or transfection with JAK3 SMART pool siRNA completely suppressed ADAMTS-4 mRNA induction without affecting the GAPDH RNA levels. (Figs. 4A and 5A ). Non-targeted negative control siRNA did not affect the expression of JAK3, ADAMTS-4 and MMP-13 expression ( Fig. 5) . Further, MMP-13 protein induction by OSM was also decreased by JAK3 inhibitor in a dose-dependent fashion (Fig. 4A and E) . Knockdown of JAK3 by SMART pool siRNA partially decreased the OSM-induced MMP-13 protein expression (Fig. 5A ). This incomplete inhibition could be due to partial knockdown of JAK3 by specific siRNA (∼ 70%) ( Fig. 5B ). SW1353 chondrocytic cell line was used in the experiments of Fig. 5 due to low transfection efficiency of human primary chondrocytes. As depicted in Fig. 5C , very high-efficiency transfection can be achieved by modified Calcium phosphate method using trypsinized and suspended cells. JAK2-specific inhibitor (AG490) dose-dependently attenuated ADAMTS-4-induction by OSM in human chondrocytes but did not inhibit OSMinduced MMP-13 expression ( Fig. 4B and D) .
Parthenolide diminishes OSM-induced ADAMTS-4 and MMP-13 expression and STAT-3-DNA binding
Parthenolide is an inhibitor of STAT1 and STAT3 phosphorylation, which prevents their dimerization and localization to nucleus [29] . Pretreatment with parthenolide (10 μM) partially (ADAMTS-4) or completely (MMP-13) inhibited OSM induction of these genes (Fig. 6A and B) . Analysis of nuclear extracts from the OSM-treated human SW1353 chondrocytic cells by EMSA revealed that OSM induced STAT3 DNA binding activity and parthenolide inhibited such binding (Fig. 6C) . Moreover, parthenolide did not affect OSM-induced c-Fos and c-Jun activation (Fig. 6D ).
PI3K/Akt pathway inhibitors down-regulate OSM-stimulated ADAMTS-4 and MMP-13 expression
Previously unknown role of PI3K/Akt pathway in ADAMTS-4 and MMP-13 induction was also investigated. PI3K inhibitor (LY294002) and Akt inhibitor (NL-71-101), suppressed OSM-induced ADAMTS-4 mRNA and MMP-13 expression in human chondrocytes. The GAPDH RNA levels were not affected by these treatments (Figs. 7 and 8) . At higher concentration, NL-71-101 also abolished MMP-13 induction (Fig. 8 ).
PI3K/Akt pathway is a downstream target of JAK/STAT cascade
To investigate the possible cross talk between JAK/STAT and Akt pathways, human chondrocytes were pretreated with the JAK3 inhibitor, stimulated with OSM and protein extracts analyzed at different time points. OSM stimulated Akt phosphorylation within 5 min that declined by 30 min. JAK3 inhibitor down-regulated this phosphorylation without affecting the total Akt levels. These results suggest that Akt is downstream of JAK3 (Fig. 9A ). To determine whether JAK3 inhibitor affected other kinase activities, human chondrocytes were pretreated with this inhibitor and phospho-ERK1/2 levels were measured (Fig. 9B ). JAK3-mediated Akt/PKB pathway activation seemed to be specific since it did not affect OSMinduced ERK1/2 phosphorylation.
Discussion
Aggrecanases and MMP-13 are the principal enzymes responsible for sequential cleavage of cartilage aggrecan and collagen respectively. Here we have shown that OSM coordinately induces the expression of both enzymes in human chondrocytes derived from femoral head of arthritic patients. With the help of specific pharmacological and genetic inhibitors we demonstrated that multiple pathways including ERK, JAK/STAT and PI3K/Akt mediate OSM induction of these proteases. There is cross talk between JAK/STAT and Akt pathways. Interruption in OSM signaling could constitute an important strategy for blocking its catabolic effects via aggrecanases and MMP-13 in arthritis.
Other studies have investigated the impact of OSM in combination with IL-1 on cartilage, however, these studies were conducted on chondrocytes derived from either animal cartilage or human knee cartilage or immortalized human chondrocyte cell line [12, 30, 31] . To be physiologically and pathologically relevant, it is important to study responses of human articular chondrocytes from specific joints. It is more appropriate to compare the effect of any cytokines in cells from the same species and origins of joints. Indeed, certain molecular differences between different human joints or chondrocyte subgroups in response to IL-1 have been demonstrated [32, 33] . We also found a high basal level of MMP-13 in some patients; this is in agreement with the previously reported results [33] , which divided human chondrocytes in two subpopulations based on the levels of MMP-13 expression.
Our results clearly and reproducibly show that OSM by itself induces cartilage degradation, which was evaluated by GAG release from aggrecan. This phenomenon could be attributed to the induction of metalloproteinases such as ADAMTS-4 and MMP-13. Contrary to our expectation from collagen degradation studies [34] , the combination of OSM and IL-1β did not have an additive effect on GAG release. It seems that maximal induction capacity of cartilage can be attained by individual treatments and cytokine combination would not further enhance this capacity for GAG release. OSM-induced cartilage degradation seems to be mediated by ADAMTS-4 and MMP-13. In the current study, the active forms of these enzymes are increased in OSM-treated cartilage. Kashiwagi et al., [27] have demonstrated that the full-length ADAMTS-4 of 70 kDa has little activity against the Glu 373 -Ala 374 site and has to be processed to display stronger activity against this site.
The responsiveness of chondrocyte to OSM and IL-1β regarding the induction of MMP-13 protein and ADAMTS-4 mRNA expression is preserved in primary cultures. OSM alone is able to induce expression of these genes even at low concentration. Our results are in disagreement with the current view, which predominantly supports the inability of OSM alone to induce MMPs and aggrecanases. This discrepancy could be due to the cell source (bovine or human), and type of chondrocyte (nasal, immortalized chondrocyte or knee [12, 30, 31] ), experimental conditions, stage of arthritis and source of OSM (commercial versus home made) [30] .
JAK/STAT pathway is intimately involved in the signaling events initiated by OSM, activation of cell surface receptors leading to MMPs and aggrecanases induction. JAK3 plays crucial role for signaling by key immunoregulatory cytokines, and selective JAK3 inhibitors are very effective in blocking immune responses both in vitro and in vivo for transplant rejection. Although, all JAK isoforms are expressed in human chondrocytes and activated by OSM, only JAK3 seemed to mediate MMP-13-induction by OSM since JAK2 inhibition had no effect on this induction; which also has been demonstrated in our previous study [22] . JAK2 or JAK3 inhibition attenuates OSM induced ADAMTS-4 gene expression. The mechanisms by which these two kinases regulate ADAMTS-4 expression upon OSM stimulation in human chondrocytes remain to be studied further. We demonstrated that OSM-induced MMP-13 via JAK2 independent mechanism. Song et al. [35] have shown that OSM stimulates human adipose tissue-derived mesenchymal stem cells proliferation through JAK3-dependent and JAK2-independent mechanisms. Therefore, it seems likely that each isoform has specific role. STAT1 and STAT3 are activated upon OSM stimulation [22] . The activated JAKs are not specific for a particular STAT substrate but the initial specificity for most STAT activation is determined by specific interactions between STATs and the respective receptors. Specific role of each STAT isoform in chondrocytes is not known, however, STAT1 or STAT3 can form a stable homodimer prior to activation [36] . STAT1 is found in an activated state in the synovium of most but not all RA patients [37] . Similarly, STAT3 is persistently activated in Zymosan-induced models of arthritis [38] . Parthenolide has been shown to block STAT3 phosphorylation on Tyr705 preventing its dimerization and translocation to nucleus [29] . Previously STAT1 was shown to be involved in the induction of MMPs and TIMP-3 by OSM [22] . Current results demonstrate that STAT3 binds to its consensus site containing oligonucleotide, an activity inhibited by parthenolide. Inhibition of the respective RNA/protein also suggests that STAT3 activity is required for OSM-induction of ADAMTS-4 and MMP-13. In an earlier study, combined OSM-IL-1 treatment did not result in direct binding of STAT3 to MMP-1 promoter but STAT3 enhanced c-fos expression and AP-1 activity [39] .
As a consequence of biological reductionism, intracellular signaling pathways were previously considered as linear cascades of MAPK, JAK/STAT and PI3 kinase pathways. However, it seems likely that these signaling pathways are part of cell specific networks with a complex cross talk. The coordinate induction of ADAMTS-4 and MMP-13 by OSM and their inhibition by U0126, JAK3 inhibitor, parthenolide, LY294002 and NL-71-101 suggests that ERK1/2, JAK3-STAT1/3, PI3K and Akt activation are needed for the expression of these proteases. The cross talk of these kinases does exist in human chondrocytes. We have previously shown that OSM induces phosphorylation of ERK1/2 in both human and bovine chondrocytes [22] . It has been demonstrated that OSM activates ERK1/2 pathway via JAK1 [40] . Here we have shown that JAK3 does not mediate OSM-induced ERK1/2 activation in human chondrocytes. In addition, JAK2 is not implicated in activation of the target genes [22] . Therefore, the requirement of JAKs for ERK1/2 activation by cytokines may be cell type-specific. The cross talk of JAK/STAT with other intracellular pathways is not limited to ERK1/2 pathway. Interestingly, it has been demonstrated that activation of PI3K pathway requires stimulation by JAKs. To gain further insight into possible interaction of the JAK/STAT and PI3K/Akt pathways, we attempted to find the sequence of these events. Inhibition of Akt phosphorylation by the JAK3-specific inhibitor suggests that Akt pathway is a downstream target of JAK3 in chondrocytes. Time-dependent phosphorylation of Akt in response to OSM suggests that this cytokine rapidly activates PI3K/Akt pathway in human chondrocytes. This observation was somewhat surprising as OSM has growth inhibitory activity (the origin of term, oncostatin) while PI3K/ Akt pathway is generally associated with cell growth and proliferation. Murine OSM (muOSM) increases synovial fibroblast proliferation, pannus formation and invasion of cartilage [5] . The intensity of such processes is augmented when OSM and TNF-α combination is used in vivo [41] . These effects of muOSM are mediated by induction of PI3K/Akt pathway in mouse fibroblast cell lines [42] . Down-regulation of both ADAMTS-4 and MMP-13 by the specific PI3K and Akt inhibitors strongly supports the requirement of this pathway in the induction of two proteases.
The observed stimulation of multiple pathways by OSM including the growth and proliferation promoting ERK-MAPK and PI3K/Akt pathways could explain diverse and sometimes contradictory (pro-inflammatory versus antiinflammatory) properties of this cytokine [43] . Due to its ability to induce TIMPs and to protect against LPS-induced TNF-α production and lethality in vivo, OSM has been regarded as an anti-inflammatory cytokine by some investigators [43] . However, our current studies suggest a tissuedamaging and pro-arthritic role for OSM. Attempts have been made to block such actions with antibodies to OSM in RAlike murine models of arthritis [6] . The signal transduction pathways identified here could provide additional targets for therapeutic interference. Agents such as parthenolide and siRNAs may also block STAT3-dependent proliferation of rheumatoid synovial fibroblasts.
Conclusion
We have shown for the first time that the expression of two major cartilage-damaging proteases is coordinately induced by OSM in human cartilage and chondrocytes, thereby supporting its catabolic role. Inhibition of ERK1/2, JAK3/STAT1/STAT3 and PI3K/Akt pathways results in down regulation of ADAMTS-4 and MMP-13 suggesting the pivotal role of these signaling cascades and their cross talk in the up-regulation.
These results also identify novel targets and their inhibitors that could be potentially useful for diminishing OSM-driven cartilage breakdown in arthritis. Inhibition of OSM and its intracellular signaling molecules could increase the efficacy of anti-IL-1 and TNF in combination therapy approaches.
